Abstract
Sex has long been relevant in patients with myelodysplastic syndromes given there is a higher prevalence1 and poorer prognosis2 among men compared with women. However, this relationship has been traditionally viewed as one that is confounded by disease genetics or caused by differential responses to therapy,3 and not necessarily as an independent prognostic factor. In The Lancet Haematology, the GenoMed4All consortium4 used large European population datasets to challenge this dogma. The authors' data show that male sex is associated with a poorer prognosis in myelodysplastic syndromes than female sex, particularly in patients with low-risk prognostic scores according to the Revised International Prognostic Scoring System (IPSS-R).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call